Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Sigma-1 Receptors: A Novel Clinical Target in Fragile X Syndrome

NCT04314856 is registered in ClinicalTrials.gov with Guido A. Davidzon, MD, SM as lead sponsor.

NCT NCT04314856
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04314856 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Sigma-1 Receptors: A Novel Clinical Target in Fragile X Syndrome
Lead sponsor
Guido A. Davidzon, MD, SM
Phase
Phase 1
Overall status
Withdrawn
Start date
January 12, 2021
Completion date
June 30, 2022
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

fragile x syndrome (fxs)